<p>根据公司在最近向证券交易委员会（SEC）提交的 13F 表格，Thrivent Financial for Lutherans 在第四季度购买了 Alnylam Pharmaceuticals, Inc.（NASDAQ:ALNY - 免费报告）的新股份。该基金购买了 20,641 股该生物制药公司的股票，价值约为 8,208,000 美元。</p>
<ul>
<li>Alnylam 股票飙升 65%：了解背后的原因</li>
</ul>
<p>其他一些机构投资者和对冲基金也增加或减少了在该公司的股份。Vanguard Group Inc.在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 2.0%。Vanguard Group Inc.目前拥有 13,565,452 股该生物制药公司的股票，价值为 6,185,846,000 美元，在此期间又购买了 268,313 股。Capital Research Global Investors 在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 0.4%。Capital Research Global Investors 目前拥有 7,222,840 股该生物制药公司的股票，价值为 3,293,516,000 美元，在上个季度又购买了 31,184 股。Groupama Asset Managment 在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 160.4%。Groupama Asset Managment 目前拥有 4,032,082 股该生物制药公司的股票，价值为 18,610,000 美元，在上个季度又购买了 2,483,697 股。Orbis Allan Gray Ltd 在第二季度将其在 Alnylam Pharmaceuticals 的股份增加了 29.8%。Orbis Allan Gray Ltd 目前拥有 2,121,412 股该生物制药公司的股票，价值为 691,771,000 美元，在上个季度又购买了 486,489 股。最后，Arrowstreet Capital Limited Partnership 在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 698.8%。Arrowstreet Capital Limited Partnership 目前拥有 1,355,609 股该生物制药公司的股票，价值为 618,158,000 美元，在上个季度又购买了 1,185,909 股。机构投资者目前拥有该公司 92.97% 的股份。</p>
<h2>内部人员买卖</h2>
<p>在其他 Alnylam Pharmaceuticals 的新闻中，执行副总裁 Kevin Joseph Fitzgerald 在 3 月 3 日（星期二）出售了 1,652 股该公司的股票。股票以 319.73 美元的平均价格出售，总价值为 528,193.96 美元。交易后，该执行副总裁直接持有 21,860 股该公司的股票，价值约为 6,989,297.80 美元。这笔交易代表了他们持股比例的 7.03% 的减少。该出售在向证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。此外，首席执行官 Yvonne Greenstreet 在 3 月 2 日（星期一）出售了 6,799 股该公司的股票。股票以 327.65 美元的平均价格出售，总交易额为 2,227,692.35 美元。交易完成后，首席执行官直接持有 98,628 股该公司的股票，价值约为 32,315,464.20 美元。这笔交易代表了他们持股比例的 6.45% 的减少。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人员出售了 21,255 股公司股票，价值为 6,930,337 美元。公司内部人员目前持有 0.86% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
<p>几位分析师对 ALNY 股票发表了看法。美国银行在 2 月 12 日（星期四）的研究报告中重申了对 Alnylam Pharmaceuticals 股票的 “买入” 评级。加拿大皇家银行在 5 月 1 日（星期五）的研究报告中将 Alnylam Pharmaceuticals 的股票目标价从 450.00 美元下调至 445.00 美元，并对该股票设定了 “跑赢大盘” 的评级。花旗集团在周二的研究报告中开始覆盖 Alnylam Pharmaceuticals 的股票。他们对该股票设定了 “买入” 评级和 380.00 美元的目标价。Freedom Capital 在 2 月 17 日（星期二）的研究报告中将 Alnylam Pharmaceuticals 的股票评级从 “持有” 上调至 “强力买入”。最后，Wall Street Zen 在 5 月 2 日（星期六）的研究报告中将 Alnylam Pharmaceuticals 的股票评级从 “持有” 上调至 “买入”。一位投资分析师对该股票给予了强力买入评级，十九位分析师给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 463.13 美元。</p>
<p><strong>查看我们关于 ALNY 的最新研究报告</strong></p>
<h2>Alnylam Pharmaceuticals 股票上涨 2.8%</h2>
<ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
<p>NASDAQ ALNY 在周三以 294.30 美元开盘。该股票的 50 日移动平均线为 312.56 美元，200 日移动平均线为 362.08 美元。该股票的市值为 392.9 亿美元，市盈率为 80.41，贝塔值为 0.31。Alnylam Pharmaceuticals, Inc.的 52 周低点为 284.19 美元，52 周高点为 495.55 美元。该公司的债务与股本比率为 0.94，速动比率为 3.06，流动比率为 3.13。</p>
<p>Alnylam Pharmaceuticals（NASDAQ:ALNY - 获取免费报告）最后一次发布财报是在 4 月 30 日（星期四）。该生物制药公司报告本季度每股收益为 1.99 美元，超出市场共识预期的 0.87 美元，超出 1.12 美元。该公司在本季度的收入为 11.7 亿美元，而分析师的预期为 11.2 亿美元。Alnylam Pharmaceuticals 的股本回报率为 85.76%，净利润率为 11.72%。该公司的季度收入同比增长 96.4%。去年同期，该公司每股收益为（0.44）美元。平均而言，股票研究分析师预测 Alnylam Pharmaceuticals, Inc.在当前年度将发布 7.36 美元的每股收益。</p>
<h2>Alnylam Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>阿尔尼拉姆制药公司（Alnylam Pharmaceuticals, Inc.）在纳斯达克上市，股票代码为 ALNY，是一家专注于 RNA 干扰（RNAi）治疗药物的发现、开发和商业化的生物制药公司。该公司成立的目的是将 RNAi 的科学发现转化为新药，阿尔尼拉姆应用小干扰 RNA（siRNA）技术来沉默致病基因。该公司开发的疗法旨在通过针对一系列罕见和更普遍疾病的潜在遗传驱动因素，提供持久的疾病修正。</p>
<p>阿尔尼拉姆已将多种基于 siRNA 的产品推进至商业化，最初使用脂质纳米颗粒递送，最近则采用 GalNAc-结合化学技术，以实现针对肝脏的靶向递送，并通过皮下给药。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过阿尔尼拉姆制药</li>
<li>HIVE 利用电力进行人工智能转型</li>
<li>深入分析 NVIDIA 最新的投资组合动向</li>
<li>布雷迪公司（Brady Corp）实现大规模人工智能驱动的突破</li>
<li>为什么家得宝的抛售可能成为一个巨大的机会</li>
</ul>
<p><strong>想知道其他对 ALNY 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取阿尔尼拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在阿尔尼拉姆制药吗？</h2>
<p>在考虑阿尔尼拉姆制药之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师，以及他们每天向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿尔尼拉姆制药并不在名单上。</p>
<p>虽然阿尔尼拉姆制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿里拉姆制药

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Thrivent Financial for Lutherans 收购了 Alnylam Pharmaceuticals 的新股份，购买了 20,641 股，价值约为 820 万美元。其他机构投资者也增加了他们的持股。内部交易包括执行副总裁 Kevin Fitzgerald 和首席执行官 Yvonne Greenstreet 的股票出售。分析师对 ALNY 保持乐观展望，给予了多个 “买入” 评级，普遍目标价为 463.13 美元。该股票目前的交易价格为 294.30 美元</p>

<p>Thrivent Financial for Lutherans bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 20,641 shares of the biopharmaceutical company's stock, valued at approximately $8,208,000.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会（SEC）提交的 13F 表格，Thrivent Financial for Lutherans 在第四季度购买了 Alnylam Pharmaceuticals, Inc.（NASDAQ:ALNY - 免费报告）的新股份。该基金购买了 20,641 股该生物制药公司的股票，价值约为 8,208,000 美元。</p>
</div><ul>
<li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>Alnylam 股票飙升 65%：了解背后的原因</li>
</ul>
</div><p>A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company's stock valued at $6,185,846,000 after acquiring an additional 268,313 shares during the period. Capital Research Global Investors grew its stake in Alnylam Pharmaceuticals by 0.4% during the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company's stock worth $3,293,516,000 after buying an additional 31,184 shares during the last quarter. Groupama Asset Managment grew its stake in Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company's stock worth $18,610,000 after buying an additional 2,483,697 shares during the last quarter. Orbis Allan Gray Ltd grew its stake in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock worth $691,771,000 after buying an additional 486,489 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Alnylam Pharmaceuticals by 698.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company's stock worth $618,158,000 after buying an additional 1,185,909 shares during the last quarter. Institutional investors own 92.97% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金也增加或减少了在该公司的股份。Vanguard Group Inc.在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 2.0%。Vanguard Group Inc.目前拥有 13,565,452 股该生物制药公司的股票，价值为 6,185,846,000 美元，在此期间又购买了 268,313 股。Capital Research Global Investors 在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 0.4%。Capital Research Global Investors 目前拥有 7,222,840 股该生物制药公司的股票，价值为 3,293,516,000 美元，在上个季度又购买了 31,184 股。Groupama Asset Managment 在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 160.4%。Groupama Asset Managment 目前拥有 4,032,082 股该生物制药公司的股票，价值为 18,610,000 美元，在上个季度又购买了 2,483,697 股。Orbis Allan Gray Ltd 在第二季度将其在 Alnylam Pharmaceuticals 的股份增加了 29.8%。Orbis Allan Gray Ltd 目前拥有 2,121,412 股该生物制药公司的股票，价值为 691,771,000 美元，在上个季度又购买了 486,489 股。最后，Arrowstreet Capital Limited Partnership 在第三季度将其在 Alnylam Pharmaceuticals 的股份增加了 698.8%。Arrowstreet Capital Limited Partnership 目前拥有 1,355,609 股该生物制药公司的股票，价值为 618,158,000 美元，在上个季度又购买了 1,185,909 股。机构投资者目前拥有该公司 92.97% 的股份。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖</h2>
</div><p>In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the firm's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president directly owned 21,860 shares of the company's stock, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 6,799 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the completion of the transaction, the chief executive officer directly owned 98,628 shares in the company, valued at approximately $32,315,464.20. The trade was a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 21,255 shares of company stock worth $6,930,337. 0.86% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Alnylam Pharmaceuticals 的新闻中，执行副总裁 Kevin Joseph Fitzgerald 在 3 月 3 日（星期二）出售了 1,652 股该公司的股票。股票以 319.73 美元的平均价格出售，总价值为 528,193.96 美元。交易后，该执行副总裁直接持有 21,860 股该公司的股票，价值约为 6,989,297.80 美元。这笔交易代表了他们持股比例的 7.03% 的减少。该出售在向证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。此外，首席执行官 Yvonne Greenstreet 在 3 月 2 日（星期一）出售了 6,799 股该公司的股票。股票以 327.65 美元的平均价格出售，总交易额为 2,227,692.35 美元。交易完成后，首席执行官直接持有 98,628 股该公司的股票，价值约为 32,315,464.20 美元。这笔交易代表了他们持股比例的 6.45% 的减少。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人员出售了 21,255 股公司股票，价值为 6,930,337 美元。公司内部人员目前持有 0.86% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 biotech powerhouses poised to thrive amid sector rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
</div><p>Several analysts have weighed in on ALNY shares. Bank of America reaffirmed a &#34;buy&#34; rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Royal Bank Of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday, May 1st. Citigroup started coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday. They set a &#34;buy&#34; rating and a $380.00 price objective on the stock. Freedom Capital raised shares of Alnylam Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 17th. Finally, Wall Street Zen raised shares of Alnylam Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $463.13.</p>
<div class="lb-trans"><p>几位分析师对 ALNY 股票发表了看法。美国银行在 2 月 12 日（星期四）的研究报告中重申了对 Alnylam Pharmaceuticals 股票的 “买入” 评级。加拿大皇家银行在 5 月 1 日（星期五）的研究报告中将 Alnylam Pharmaceuticals 的股票目标价从 450.00 美元下调至 445.00 美元，并对该股票设定了 “跑赢大盘” 的评级。花旗集团在周二的研究报告中开始覆盖 Alnylam Pharmaceuticals 的股票。他们对该股票设定了 “买入” 评级和 380.00 美元的目标价。Freedom Capital 在 2 月 17 日（星期二）的研究报告中将 Alnylam Pharmaceuticals 的股票评级从 “持有” 上调至 “强力买入”。最后，Wall Street Zen 在 5 月 2 日（星期六）的研究报告中将 Alnylam Pharmaceuticals 的股票评级从 “持有” 上调至 “买入”。一位投资分析师对该股票给予了强力买入评级，十九位分析师给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 463.13 美元。</p>
</div><p><strong>View Our Latest Research Report on ALNY</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ALNY 的最新研究报告</strong></p>
</div><h2>Alnylam Pharmaceuticals Stock Up 2.8%</h2>
<div class="lb-trans"><h2>Alnylam Pharmaceuticals 股票上涨 2.8%</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>NASDAQ ALNY opened at $294.30 on Wednesday. The stock has a fifty day moving average of $312.56 and a 200-day moving average of $362.08. The stock has a market capitalization of $39.29 billion, a P/E ratio of 80.41 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 52 week low of $284.19 and a 52 week high of $495.55. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13.</p>
<div class="lb-trans"><p>NASDAQ ALNY 在周三以 294.30 美元开盘。该股票的 50 日移动平均线为 312.56 美元，200 日移动平均线为 362.08 美元。该股票的市值为 392.9 亿美元，市盈率为 80.41，贝塔值为 0.31。Alnylam Pharmaceuticals, Inc.的 52 周低点为 284.19 美元，52 周高点为 495.55 美元。该公司的债务与股本比率为 0.94，速动比率为 3.06，流动比率为 3.13。</p>
</div><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The company had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business's revenue for the quarter was up 96.4% on a year-over-year basis. During the same period last year, the firm earned ($0.44) EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.</p>
<div class="lb-trans"><p>Alnylam Pharmaceuticals（NASDAQ:ALNY - 获取免费报告）最后一次发布财报是在 4 月 30 日（星期四）。该生物制药公司报告本季度每股收益为 1.99 美元，超出市场共识预期的 0.87 美元，超出 1.12 美元。该公司在本季度的收入为 11.7 亿美元，而分析师的预期为 11.2 亿美元。Alnylam Pharmaceuticals 的股本回报率为 85.76%，净利润率为 11.72%。该公司的季度收入同比增长 96.4%。去年同期，该公司每股收益为（0.44）美元。平均而言，股票研究分析师预测 Alnylam Pharmaceuticals, Inc.在当前年度将发布 7.36 美元的每股收益。</p>
</div><h2>Alnylam Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Alnylam Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.</p>
<div class="lb-trans"><p>阿尔尼拉姆制药公司（Alnylam Pharmaceuticals, Inc.）在纳斯达克上市，股票代码为 ALNY，是一家专注于 RNA 干扰（RNAi）治疗药物的发现、开发和商业化的生物制药公司。该公司成立的目的是将 RNAi 的科学发现转化为新药，阿尔尼拉姆应用小干扰 RNA（siRNA）技术来沉默致病基因。该公司开发的疗法旨在通过针对一系列罕见和更普遍疾病的潜在遗传驱动因素，提供持久的疾病修正。</p>
</div><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p>
<div class="lb-trans"><p>阿尔尼拉姆已将多种基于 siRNA 的产品推进至商业化，最初使用脂质纳米颗粒递送，最近则采用 GalNAc-结合化学技术，以实现针对肝脏的靶向递送，并通过皮下给药。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Alnylam Pharmaceuticals</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过阿尔尼拉姆制药</li>
<li>HIVE 利用电力进行人工智能转型</li>
<li>深入分析 NVIDIA 最新的投资组合动向</li>
<li>布雷迪公司（Brady Corp）实现大规模人工智能驱动的突破</li>
<li>为什么家得宝的抛售可能成为一个巨大的机会</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ALNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 ALNY 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取阿尔尼拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ALNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在阿尔尼拉姆制药吗？</h2>
</div><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿尔尼拉姆制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师，以及他们每天向客户推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿尔尼拉姆制药并不在名单上。</p>
</div><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿尔尼拉姆制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Thrivent Financial for Lutherans Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Market Beat

Invesco Nasdaq Biotechnology ETF

美国制药 ETF - iShares

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

Direxion Daily Biotech Top 5 Bull 2X ETF

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

医疗业 ETF - SPDR

美国银行

加拿大皇家银行

花旗

Argenx

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

路德会 Thrivent 金融购入了阿里拉姆制药公司（Alnylam Pharmaceuticals, Inc.）的新股份，股票代码$ALNY